- In January 2025, Inventia Life Science introduced the RASTRUM Allegro, an advanced 3D cell culture technology designed to accelerate drug discovery and development. This platform enables high-throughput screening by automating the creation of complex 3D cell models, enhancing the efficiency and scalability of preclinical research
- In November 2024, Emulate Inc. announced the expansion of its organ-on-a-chip technology, integrating 3D cell culture systems to better mimic human physiology. This advancement aims to improve the predictive accuracy of in vitro models in drug testing, reducing reliance on animal models and enhancing translational research outcome
- In September 2024, Corning Incorporated expanded its 3D cell culture product line by introducing new scaffold-based platforms that offer improved cell growth and differentiation. These innovations are tailored to support applications in cancer research, regenerative medicine, and personalized therapeutics, reflecting the company's commitment to advancing cell culture technologies
- In August 2024, Thermo Fisher Scientific unveiled a new range of advanced hydrogels designed for 3D cell culture applications. These hydrogels provide a more physiologically relevant environment for cell growth, facilitating more accurate modeling of tissue architecture and function, thereby enhancing research in drug discovery and disease modelling
- In July 2024, Lonza Group AG launched innovative 3D bioprinting solutions that integrate with existing 3D cell culture systems. These solutions aim to create more complex tissue models, enabling researchers to study cellular interactions in a more in vivo-like environment, which is crucial for advancing tissue engineering and regenerative medicine
